Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBY: Crenezumab in Mild to Moderate Alzheimer's Disease
NCT01343966Phase 2Completed
- Sponsor
- Genentech
- Start
- Apr 2011
- Primary completion
- Feb 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of crenezumab in Alzheimer's disease (AD) (4 arms), sponsored by Genentech. Primary endpoints: Alzheimer's Disease Assessment Scale Cognitive Subscale at 73 weeks and Clinical Dementia Rating Sum of Boxes at 73 weeks. Started Apr 2011; status: completed.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01343966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01343966.